William Tew

18PUBLICATIONS
164CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCancer geneticsCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Mar 25, 2026
A Phase II Trial of Olaparib plus Pembrolizumab in Patients with Recurrent Copy Number-High/p53-Abnormal Endometrial Cancer.

Maria M Rubinstein, Jennifer Y Ge, Qin Zhou

|Jan 22, 2025
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Clinical Insights.

William P Tew, Christina Lacchetti, Stéphanie Gaillard

|Jan 22, 2025
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update.

Stéphanie Gaillard, Christina Lacchetti, Deborah K Armstrong

|Nov 19, 2024
A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer.

Angela K Green, Qin Zhou, Alexia Iasonos

|Dec 15, 2023
Top advances of the year: Ovarian cancer.

Melissa A Lumish, Elise C Kohn, William P Tew

|Nov 14, 2023
Falls prechemotherapy and toxicity-related hospitalization during adjuvant chemotherapy for breast cancer in older women: Results from the prospective multicenter HOPE trial.

Jingran Ji, Marie Bae, Can-Lan Sun

Pageof 3

Frequent Collaborators

5 joint publications

Alexia Iasonos

5 joint publications

Hyman Muss

5 joint publications

Roisin E O'Cearbhaill

4 joint publications

Ying L Liu